| Code | CSB-RA023984MB14HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Sytalizumab, targeting TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as CD137 or 4-1BB. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a critical role in regulating immune cell activation, proliferation, and survival. Upon binding to its ligand 4-1BBL, TNFRSF9 delivers potent costimulatory signals that enhance T cell-mediated immune responses and promote antitumor immunity. This pathway has significant implications in cancer immunotherapy, autoimmune diseases, and viral infections.
Sytalizumab represents an investigational therapeutic antibody designed to modulate TNFRSF9 signaling for immune regulation. This biosimilar antibody provides researchers with a valuable tool for exploring TNFRSF9 biology, investigating immune checkpoint mechanisms, and studying T cell activation dynamics in various disease models. It supports investigations into cancer immunology, immune modulation strategies, and the development of novel immunotherapeutic approaches targeting costimulatory pathways.
There are currently no reviews for this product.